Stock under Close Observation: Athenex Inc (NASDAQ: ATNX)

The business leapt 6.74% in previous week and decreased -16.19% in one month. Throughout the past three-month duration the stock dropped -40.43% and increased 6.95% in previous 6 month. Throughout the twelve month it lost -11.72% and year to date efficiency of -13.95%.

Dr. Rudolf Kwan, Chief Medical Officer of Athenex, stated, “We enjoy with the continued development of the tirbanibulin ointment program. We just recently finished pre-NDA consultation with the U.S. FDA and our preparations for the NDA submission in the U.S. are on track. We eagerly anticipate dealing with our partner, Almirall, towards commercializing this item, if approved.”

Athenex Inc (NASDAQ: ATNX) began its trading session with the cost $10.5 and closed at rate of $10.92 by scoring 3.21%. Day range of the stock was $10.11 – $11.13. ATNX stock traded with total volume of 0 shares while the average trading capacity stayed 1188487 shares. Profits per share was $-1.82. ATNX has overall market capitalization of $844039565.

In December 2017, Athenex gave Almirall, S.A., a leading skin-health focused international pharmaceutical company, an exclusive license to research, commercialize and establish tirbanibulin in the U.S. and European countries, consisting of Russia. Athenex is accountable for the U.S. FDA regulative for tirbanibulin lotion in AK. Almirall will employ its proficiency to support the development in Europe and likewise to advertise the item in the defined territories.

Athenex, Inc. (Nasdaq: ATNX) today reported a progress upgrade from partner Almirall on tirbanibulin lotion (likewise called ALM14789, formerly known as KX-01 or KX2-391) for the treatment of actinic keratosis (AK).

2021's Most Anticipated Growth & Wealth-Building Opportunity

Join Thousands of Early Adopters Just Like You Who Want to Grow Capital and Truly Understand Cryptocurrency Together

Robert Hernandez

Robert Hernandez – Health and Biotech I am Robert Hernandez, I have done my bachelor’s in English literature, and further on I did my master’s in Medicines. My most preferred genre of writing is health and biotech. I have been writing from the past 6 years about articles, web content, and blogs. In my career and education, I like to play along with work. I have also been a teacher in the past for 2 years. I use to teach business and technical writing in a very famous university. However, most recently I am working as an instructor, designer, and training writer. I enjoy socializing a lot. I am a very big extrovert when it comes to nature. A part from all this I enjoy exploring the world and traveling makes me happy.

2021's Most Anticipated Growth & Wealth-Building Opportunity

Join Thousands of Early Adopters Just Like You Who Want to Grow Capital and Truly Understand Cryptocurrency Together

Close Bitnami banner
Bitnami